IRIS International and Fisher Healthcare Sign Distribution Agreement for ThermoBrite Elite(R)
News Feb 14, 2012
Iris Sample Processing and Fisher HealthCare launched their collaboration at the 2012 Thermo Fisher Scientific Customer Channels National Sales Meeting last week in Las Vegas, and will subsequently actively promote the ThermoBrite Elite platform to their combined customer base.
"We are enthusiastic about partnering with Fisher HealthCare and expect clinical laboratories will be first movers on this new technology followed shortly by discovery and translational researchers. The level of pre-launch excitement by the market reinforces our belief that this is the right product with the right features at the right time. Our automated ThermoBrite Elite is the natural line extension to the installed base of approximately 5,000 ThermoBrite instruments and will significantly enhance our competitive positioning in the high growth cytogenetic instrumentation market," stated Bill Standwill, VP Global Sales & Marketing for the Iris Sample Processing division.
"The ThermoBrite Elite provides an automated solutions approach for FISH sample preparation in a compact, easy to use system with improved labor efficiencies and process reliability. Expanding our relationship with Fisher HealthCare provides a significant domestic sales channel for the ThermoBrite Elite and our future molecular products in this fast growing market," said Robert Mello, President of the Iris Sample Processing Division.
"We at Fisher HealthCare are excited about our partnership with Iris Sample Processing, and are proud to add the ThermoBrite Elite line to our portfolio of industry leading molecular diagnostics solutions. We are confident that our extensive base of clinical lab customers will immediately recognize the significant value offered by the ThermoBrite Elite," stated Mark Zacur, Vice President of Marketing and Business Development at Fisher HealthCare.
With the increasing rate of adoption for FISH testing as a standard protocol in cancer diagnostics development and application, laboratories performing as few as 10 tests per day can benefit from this automation. It is estimated that there are approximately 4,000 of these laboratories globally in the clinical and research market that will be targeted.
FISH uses nucleic acid probes, which are segments of labeled DNA that are designed to hybridize or bind to the target DNA of a positive specimen. The probes are labeled with fluorescent or chromogenic molecules to enable the identification of genetic abnormalities, providing valuable information about cancer and other genetic diseases.
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019